UNSPSC 51382302: Enfenamic acid

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 05KO5G76R2, chemically known as benzoic acid, 2-(phenethylamino)- but generally known as enfenamic acid, which bears US NIH Compound Identifier 31635. European Medicines Agency schedules Enfenamic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06529MIG.

UNSPSC 51382302 Enfenamic acid is a Commodity code that in recent state and local practice covers pharmaceutical procurement far broader than the code name suggests—principally generic multi-source drugs, over-the-counter products, and opioid-reversal medications sourced through cooperative purchasing agreements and direct county health initiatives. State and local issuing bodies under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple states. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive IFB; the Texas Health and Human Services Commission has issued an RFI to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has called for generic pharmaceutical and OTC product manufacturers through a formal RFP serving participating state and local facilities across Minnesota and Oregon. The work involves both supply of physical products with specific NDC codes, packaging, and manufacturing certifications and establishment of pricing and distribution agreements with authorized wholesalers or direct delivery to end-user facilities.

Recent activity appears concentrated in the upper Midwest and Southeast, with MMCAP's cooperative structure reaching Minnesota and Oregon, the Texas HHS Commission covering Texas, and Seminole County representing Florida market participation. MMCAP's RFP (S1070000015802, due March 26, 2026) is the largest-scale recent opportunity, requiring compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintenance of relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and a 3 percent administrative fee; the contract term runs two years for new responders with optional extensions. Seminole County's IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, a two-year initial term, and one-year renewal option. Texas HHS's RFI (HHS0017013, posted April 3, 2026) serves as exploratory market intelligence gathering rather than formal competitive bidding and does not establish immediate contract awards or budget commitments.